Prediction of cancer outcome with microarrays - Reply

被引：3

作者：

Klijn, JGM

Wang, YX

Atkins, D

Foekens, JA

机构：

[1] Erasmus Med Ctr, Dept Med Oncol, NL-3015 GE Rotterdam, Netherlands

[2] Veridex LLC, San Diego, CA USA

[3] Veridex LLC, Raritan, NJ USA

来源：

LANCET | 2005年 / 365卷 / 9472期

关键词：

D O I：

10.1016/S0140-6736(05)66543-9

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1686 / 1686

页数：1

共 5 条

[1]

Clarke M, 1998, LANCET, V351, P1451

[2] PATHOLOGICAL PROGNOSTIC FACTORS IN BREAST-CANCER .1. THE VALUE OF HISTOLOGICAL GRADE IN BREAST-CANCER - EXPERIENCE FROM A LARGE STUDY WITH LONG-TERM FOLLOW-UP [J].

ELSTON, CW ;

ELLIS, IO .

HISTOPATHOLOGY, 1991, 19 (05) :403-410

[3] Meeting highlights:: Updated international expert consensus on the primary therapy of early breast cancer [J].

Goldhirsch, A ;

Wood, WC ;

Gelber, RD ;

Coates, AS ;

Thürlimann, B ;

Senn, HJ .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (17) :3357-3365

[4] Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling [J].

Jansen, MPHM ;

Foekens, JA ;

van Staveren, IL ;

Dirkzwager-Kiel, MM ;

Ritstier, K ;

Look, MP ;

Meijer-van Gelder, ME ;

Sieuwerts, AM ;

Portengen, H ;

Dorssers, LCJ ;

Klijn, JGM ;

Berns, EMJJ .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (04) :732-740

[5] Annual hazard rates of recurrence for breast cancer after primary therapy [J].

Saphner, T ;

Tormey, DC ;

Gray, R .

JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (10) :2738-2746

← 1 →